RxDoctor Payments Data

Christopher Foret, MD

Family Medicine · Folsom, LANPI 1245251602

Payments from drug & device makers

$2,796in general payments, 2019–2025

Across 29 payments — averaging $96.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Supernus Pharmaceuticals, Inc.$67
  • Ultragenyx Pharmaceutical Inc.$67
  • AbbVie$61
  • Pfizer$55
  • Exact Sciences$52
  • plus $243 from 12 others

What the payments were for

  • Speaking & faculty fees$2,25080%
  • Food & beverage$48517%
  • Education$612%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,796 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$100,170
Medicare patients
307
Services billed
1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide119$183,578
OzempicSemaglutide94$108,068
JardianceEmpagliflozin107$88,609
EliquisApixaban96$80,402
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog55$56,424
MounjaroTirzepatide23$38,892
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog54$30,672
XareltoRivaroxaban33$28,768
FarxigaDapagliflozin Propanediol24$27,529
Tresiba Flextouch U-200Insulin Degludec24$24,118
MyrbetriqMirabegron31$23,247
Repatha SureclickEvolocumab28$21,921
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,711
JanuviaSitagliptin Phosphate15$16,666
Breo ElliptaFluticasone/Vilanterol30$13,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$15$94,064118 claims
PfizerEliquis$55$80,40296 claims
AstraZenecaFarxiga, Symbicort$16$35,51354 claims
GSKTrelegy Ellipta, Breo Ellipta$30$31,88449 claims
AbbVieLinzess, Synthroid$61$11,07292 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Folsom

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →